DK1483265T3 - Purinderivater som kinaseinhibitorer - Google Patents

Purinderivater som kinaseinhibitorer

Info

Publication number
DK1483265T3
DK1483265T3 DK03711146T DK03711146T DK1483265T3 DK 1483265 T3 DK1483265 T3 DK 1483265T3 DK 03711146 T DK03711146 T DK 03711146T DK 03711146 T DK03711146 T DK 03711146T DK 1483265 T3 DK1483265 T3 DK 1483265T3
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
purine derivatives
purine
derivatives
formula
Prior art date
Application number
DK03711146T
Other languages
Danish (da)
English (en)
Inventor
Joshua Ryan Clayton
Thomas Albert Engler
Kelly Wayne Furness
Jon Kevin Reel
Clive Gideon Diefenbacher
James Robert Henry
Sushant Malhotra
Angela Lynn Marquart
David Mendel
Timothy Paul Burkholder
Yihong Li
John Morris Sullivan
Brian Raymond Berridge
Charles Edward Ruegg
Johnathan Alexander Mclean
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1483265T3 publication Critical patent/DK1483265T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
DK03711146T 2002-03-05 2003-03-04 Purinderivater som kinaseinhibitorer DK1483265T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36224502P 2002-03-05 2002-03-05
PCT/US2003/005050 WO2003076442A1 (fr) 2002-03-05 2003-03-04 Derives de la purine en tant qu'inhibiteurs de la kinase

Publications (1)

Publication Number Publication Date
DK1483265T3 true DK1483265T3 (da) 2007-03-19

Family

ID=27805149

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03711146T DK1483265T3 (da) 2002-03-05 2003-03-04 Purinderivater som kinaseinhibitorer

Country Status (16)

Country Link
US (4) US7491716B2 (fr)
EP (1) EP1483265B1 (fr)
JP (1) JP4414232B2 (fr)
KR (1) KR100974770B1 (fr)
CN (1) CN1312154C (fr)
AT (1) ATE346070T1 (fr)
AU (1) AU2003215325B8 (fr)
BR (1) BR0308243B1 (fr)
CA (1) CA2477967C (fr)
CY (1) CY1109006T1 (fr)
DE (1) DE60309848T2 (fr)
DK (1) DK1483265T3 (fr)
ES (1) ES2276048T3 (fr)
IL (2) IL163781A0 (fr)
PT (1) PT1483265E (fr)
WO (1) WO2003076442A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040091113A (ko) * 2002-03-08 2004-10-27 일라이 릴리 앤드 캄파니 피롤-2,5-디온 유도체 및 ｇｓｋ-3 억제제로서 그의 용도
GB0212049D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
CN101941970B (zh) 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
US7968535B2 (en) * 2005-05-04 2011-06-28 Develogen Atkiengesellschaft Use of azapaullones for preventing and treating pancreatic autoimmune disorders
EP1885454A2 (fr) * 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Utilisation des inhibiteurs gsk-3 dans la prevention et le traitement des maladies auto-immunes pancreatiques
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
CN101443314B (zh) * 2006-03-13 2014-04-09 杏林制药株式会社 作为gsk-3抑制剂的氨基喹诺酮类
EP1845098A1 (fr) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, leur procédés de préparation et leur utilisation comme ligands du recepteur GABA
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2061767B1 (fr) 2006-08-08 2014-12-17 Sanofi Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101302216B (zh) * 2007-05-11 2011-08-10 上海睿智化学研究有限公司 稠环吲哚类化合物的制备方法
EP2170870B1 (fr) 2007-06-22 2014-03-05 ArQule, Inc. Dérivés de pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine et thiosuccinimide, compositions et procédés pour le traitement d'un cancer
WO2009002807A2 (fr) 2007-06-22 2008-12-31 Arqule, Inc. Compositions et procédés de traitement du cancer
KR20100024494A (ko) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
SG175207A1 (en) * 2009-04-14 2011-11-28 Lilly Co Eli Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2493889B1 (fr) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. Dérivés d'imidazo[1,2-b]pyridazine et leur utilisation en tant qu'inhibiteurs pde10
WO2011082266A2 (fr) 2009-12-30 2011-07-07 Arqule, Inc. Composés hétérocycliques substitués
AU2011208530A1 (en) 2010-01-19 2012-08-09 Astrazeneca Ab Pyrazine derivatives
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012088491A2 (fr) * 2010-12-23 2012-06-28 Arqule, Inc. Compositions de pyrroloquinoléinyl-pyrrolidine-2,5-dione et procédés pour préparer et utiliser ceux-ci
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2863909B1 (fr) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinaisons comprenant des dérivés de 4-méthyl-[1,2,4]triazolo[4,3-a]quinoxaline comme inhibiteurs de la pde 2 et des inhibiteurs de la pde 10 pour utilisation dans le traitement de troubles neurologiques ou métaboliques
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
WO2014098000A1 (fr) * 2012-12-17 2014-06-26 Daiichi Sankyo Company, Limited Procédé de préparation d'un hétérocycle tricyclique
WO2014208586A1 (fr) 2013-06-26 2014-12-31 第一三共株式会社 Procédé de production d'un composé hétérocyclique tricyclique
EP2818471A1 (fr) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composés bicycliques d'azote en tant qu'inhibiteurs de Scyl1 et Grk5
CA3048220A1 (fr) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. Composes 1h-pyrrole-2,5-dione et leurs procedes d'utilisation pour induire un auto-renouvellement de cellules de support souches/progenitrices
CA3057499A1 (fr) 2017-04-11 2018-10-18 Frequency Therapeutics, Inc. Procedes pour la proliferation des cellules souches des follicules pileux
WO2019126686A1 (fr) * 2017-12-21 2019-06-27 Frequency Therapeutics, Inc. Composés 1,2-dihydro-3h-pyrazol-3-one et leurs procédés d'utilisation
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
US20200121681A1 (en) 2018-10-17 2020-04-23 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
CA3123215C (fr) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders
CN112390794B (zh) * 2019-08-19 2023-05-26 鲁南制药集团股份有限公司 一种米诺膦酸关键中间体的制备方法
CN115925622A (zh) * 2023-02-10 2023-04-07 山西永津集团有限公司 一种3-氰基吡啶-2-基氨基甲酸叔丁酯的合成方法
CN115974850B (zh) * 2023-02-16 2024-08-06 中国药科大学 一类作为akr1c3抑制剂的化合物及其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (sk) 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
WO1998016528A1 (fr) * 1996-10-11 1998-04-23 Chiron Corporation Inhibiteurs puriques de glycogene synthase kinase 3 (gsk3)
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
WO2001044235A2 (fr) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents et methodes de traitement des maladies hyperplasiques
US6867198B2 (en) * 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
CZ2003555A3 (en) 2000-07-27 2004-03-17 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
YU46603A (sh) 2000-12-08 2006-05-25 Ortho-Mcneil Pharmaceutical Inc. Indazolil-supstituisana jedinjenja pirolina, kao inhibitori kinaze
MXPA03005139A (es) 2000-12-08 2004-01-29 Ortho Mcneil Pharm Inc Compuestos macroheterociclicos utiles como inhibidores de cinasa.

Also Published As

Publication number Publication date
US7491716B2 (en) 2009-02-17
AU2003215325B8 (en) 2008-10-09
ES2276048T3 (es) 2007-06-16
IL163781A0 (en) 2005-12-18
CN1312154C (zh) 2007-04-25
EP1483265B1 (fr) 2006-11-22
EP1483265A1 (fr) 2004-12-08
AU2003215325A1 (en) 2003-09-22
DE60309848D1 (de) 2007-01-04
BR0308243B1 (pt) 2014-08-26
BR0308243A (pt) 2005-01-11
CA2477967C (fr) 2010-08-10
IL163781A (en) 2010-04-15
AU2003215325B2 (en) 2008-09-18
US8058425B2 (en) 2011-11-15
JP2005526072A (ja) 2005-09-02
US20050090483A1 (en) 2005-04-28
DE60309848T2 (de) 2007-05-16
CA2477967A1 (fr) 2003-09-18
US20090105229A1 (en) 2009-04-23
WO2003076442A1 (fr) 2003-09-18
JP4414232B2 (ja) 2010-02-10
KR20040087338A (ko) 2004-10-13
US20110294792A1 (en) 2011-12-01
US8022065B2 (en) 2011-09-20
KR100974770B1 (ko) 2010-08-06
CY1109006T1 (el) 2014-07-02
ATE346070T1 (de) 2006-12-15
US20110207721A1 (en) 2011-08-25
CN1639165A (zh) 2005-07-13
PT1483265E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
ATE400567T1 (de) Kinaseinhibitoren
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
UA85505C2 (en) Kinase inhibitors
IL163777A0 (en) Kinase inhibitors
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
EA200501563A1 (ru) Пролекарства ингибиторов киназы pi-3
NO20081636L (no) FAP - inhibitorer
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
EA200801199A1 (ru) Ингибиторы киназы
GB0100889D0 (en) Compounds
MXPA04008613A (es) N-aminoacetil-pirrolidina-2-carbonitrilos y su uso como inhibidores de ddp-iv.
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
DK1699797T3 (da) Pyrrolotriazinforbindelser som kinasehæmmere
NO20042253L (no) Aminobenzamidderivater som glykogensyntase-kinase 3beta-inhibitorer
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
ATE552834T1 (de) Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7